Companies

STENTYS is to acquire the assets of Cappella Peel Away Inc to enhance delivery of its next Self-Apposing Stent

Covidien plc, has announced the European commercial launch of its Nellcor™ Respiration Rate System

St. Jude Medical, Inc. has completed its acquisition of CardioMEMS, Inc., developer of the CardioMEMS™ HF System. The acquisition was completed on May 30, 2014.

New data presented at EuroPCR 2014 in Paris suggests impressive performance at six months for the Lotus™ Valve System, with 79.8 percent of patients showing no paravalvular aortic regurgitation at six months with no cases of severe paravalvular aortic regurgitation in any patient.

Medtronic and Edwards Lifesciences have buried the hatchet in their ongoing patent disputes with the former coughing up an immediate $750 million plus future amounts based on sales.

Preliminary results from the St. Jude Medical EnligHTN III study suggest the company’s second-generation EnligHTN™ renal denervation system provides safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure.

Ethicon Endo-Surgery has launched its HARMONIC ACE®+7 Shears with Advanced Hemostasis, the first purely ultrasonic device with a 7 mm sealing indication. It claims the system outperforms its rival LigaSure™device when it comes to burst pressure.

The big news in transcatheter aortic valve development is that St. Jude Medical, Inc. has seen the first patient implants in the Portico™ Re-sheathable Transcatheter Aortic Valve System U.S. IDE Trial (PORTICO trial). The trial is evaluating the Portico™ Transcatheter Aortic Valve System, claimed by St. Jude to be the first aortic heart valve that is repositionable until fully deployed.

Less than six weeks after making the announcement that it was to acquire AccessClosure, Cardinal Health has now seen the deal completed, marking the start of its Interventional Vascular journey. The $320 million acquisition was an all-cash transaction.

In a new study, St.Jude’s Quadripolar left ventricular pacing system demonstrated 53% reduction in hospitalization translating into 62% overall cost reduction compared with its non-Quadripolar system.

Biotronik says the U.S. FDA has approved its Entovis pacemaker system with ProMRI® technology. The Entovis system allows patients to undergo MRI scans with a limited exclusion zone. FDA approval covers both single chamber (SR-T) and dual chamber (DR-T) Entovis pacemakers when implanted with Setrox pacing leads.

One of three judges has departed the room. Then his replacement votes against his view. Then someone who voted against him last time, changes her mind. Not like this is important or anything.

New retrospective data presented at the World Institute of Pain (WIP) 7th World Congress demonstrates that Boston Scientific’s Precision Spectra™ Spinal Cord Stimulator (SCS) System provided sustained and highly significant relief of low-back pain six months after implantation.

A new, randomized study, supported by Boston Scientific, presented at this year’s HRS event suggests that ICD patients do equally well, regardless of whether their implant was defib tested at the time of implantation.

St. Jude Medical, Inc., has announced results of the TOCCASTAR clinical trial, the first prospective, randomized study of contact-force ablation technology for the treatment of paroxysmal atrial fibrillation (AF). The trial met its primary endpoints and supplements the growing body of evidence that supports the safety and effectiveness of contact-force ablation technology.

Medtronic, Inc. has gained CE Mark approval and will now launch its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P in Europe.